Fig 1.
Examples of IHC staining for p53.
(original magnification: ×200).
Table 1.
Scoring criteria for p53 IHC staining.
Table 2.
Clinicopathological features of the 91 patients who received radical cystectomy.
Fig 2.
Examples of GATA3, CK20 and CK5/6 staining.
(A) Two examples showing reciprocal staining patterns of CK20 and CK5/6. (B) Two examples showing diffuse coexpression of GATA3 and CK5/6.(original magnification, 200×).
Table 3.
Correlation among GATA3, CK20, and CK5/6 staining percentages and Ki-67 index.
Table 4.
Association between Ki-67 and other IHC markers.
Fig 3.
Kaplan–Meier curves regarding the 78 patients not receiving neoadjuvant chemotherapy.
(A, B) DSS and RFS stratified by T stage. (C, D) DSS and RFS stratified by nodal status. (E, F) DSS and RFS stratified by GATA3 expression.
Table 5.
Univariate and multivariate Cox regression analysis of clinical outcomes in 78 patients not receiving neoadjuvant chemotherapy.